Triple Combination Therapy for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies, particularly those involving PD-1 and CTLA-4 immune checkpoint inhibitors, often fail to respond effectively in patients, leading to undesirable toxic effects, and there is a need for improved treatment regimens that offer better outcomes, especially for cancers with poor prognosis or poor tolerance to existing medicines.
Innovation Solution
A combination therapy using a LAG-3 protein or derivative that binds to MHC class II molecules, a programmed cell death protein-1 (PD-1) pathway inhibitor, and a chemotherapy agent, administered simultaneously or sequentially, to enhance cancer treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If PD-1 and CTLA-4 immune checkpoint inhibitors are used alone, then the treatment is simple to administer, but the response rate is insufficient and many patients fail to respond
Solution Approach 1:
The patent combines multiple immune checkpoint inhibitors (LAG-3, PD-1, CTLA-4) and chemotherapy agents into a triple combination therapy regimen. This merging of multiple therapeutic mechanisms addresses the insufficient response rate by targeting multiple immune checkpoint pathways simultaneously while maintaining a structured administration protocol that builds upon the simplicity of single-agent therapy.
Solution Approach 2:
The treatment regimen uses a composite therapeutic approach combining different classes of agents: LAG-3 protein or derivative, PD-1 pathway inhibitor, and chemotherapy agent. This composite therapy leverages the synergistic effects of immunomodulation through multiple checkpoints combined with direct cytotoxic action from chemotherapy, thereby improving overall response rate while managing complexity.
2Reliability
If combinations of immune checkpoint inhibitors (IO-IO) are used to improve response rates, then the therapeutic efficacy is enhanced, but undesirable toxic effects occur
Solution Approach 1:
The patent specifies optimized dosage ranges and administration schedules for each component of the triple combination therapy. By carefully controlling the parameters of drug dosing (LAG-3 at 3-30 mg, PD-1 inhibitor at 1-10 mg/kg, chemotherapy at 50-200 mg/m2) and timing (every 2-4 weeks), the regimen achieves enhanced therapeutic efficacy while minimizing toxic effects through precise parameter optimization.
Solution Approach 2:
The LAG-3 protein or derivative acts as an intermediary that binds to MHC class II molecules and activates antigen-presenting cells, thereby enhancing the overall immune response. This intermediary mechanism amplifies the effect of PD-1 inhibition and chemotherapy by improving antigen presentation and T-cell activation, allowing for potentially lower doses of other agents and reduced toxicity.
3Reliability
If combinations of immune checkpoint inhibitors with chemotherapy (chemo-IO) are used to improve response rates, then the therapeutic benefit is increased, but undesirable toxic effects occur
Solution Approach 1:
The patent establishes specific dosage parameters for the chemotherapy agent (50-200 mg/m2 every 2-4 weeks) when used in combination with LAG-3 and PD-1 inhibitor. This parameter optimization ensures that the chemotherapy delivers sufficient cytotoxic effect to improve response rate while the immunomodulatory agents enhance immune surveillance, potentially allowing for reduced chemotherapy dosing and minimized toxic effects.
Solution Approach 2:
The LAG-3 protein or derivative serves as an intermediary that bridges chemotherapy and immune response by activating antigen-presenting cells through MHC class II binding. This enhances the immunogenicity of chemotherapy-induced tumor cell death, improving the therapeutic benefit of chemo-IO combination while potentially reducing the chemotherapy dose required and thereby minimizing toxic effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The triple combination therapy effectively treats various cancers by boosting the immune response, reducing tumor growth, and improving clinical benefits such as response rate and progression-free survival, while minimizing side effects and reducing the doses of individual components, thus offering a more effective and safer treatment option.
Implementation Method 1
LAG-3 in particular has emerged as a promising checkpoint and several companies are developing new inhibitors that target this checkpoint. The aim of a LAG-3 inhibitor, as with the currently approved PD-1 and CTLA-4 inhibitors, is to block the down-regulation of the immune system
Implementation Method 2
This activates the APCs causing them to become professional antigen presenting cells, thereby presenting antigen to the adaptive immune system. This leads to activation and proliferation of CD4+(helper) and CD8+(cytotoxic) T cells
Implementation Method 3
PD-1 and CTLA-4 immune checkpoint inhibitors such as OPDIVO (nivolumab), KEYTRUDA (pembrolizumab) and YERVOY (ipilimumab) have become the standard of care therapies for many forms of cancer
Implementation Method 4
In some cases, these new medicines are combined with chemotherapy (chemo-IO) to improve response rates, although this can lead to undesirable toxic effects
Data Source
AI summary
Use of a LAG-3 protein or derivative thereof as part of a combination therapy for the treatment of cancer is described. In particular. (a) a LAG-3 protein, or a derivative thereof that is able to bind to MIC class II molecules. (b) a programmed cell death protein-1 (PD-1) pathway inhibitor, and (c) a chemotherapy agent, for use in preventing, treating, or ameliorating a cancer in a subject is described. Combined preparations, and pharmaceutical compositions, comprising: (a) a LAG-3 protein, or derivative thereof that is able to bind to MHC class II molecules: (b) a programmed cell death protein-1 (PD-1) pathway inhibitor; and (c) a chemotherapy agent, are also described. Use of the combined preparations and compositions as medicaments, in particular for the prevention, treatment, or amelioration of cancer are also described, as are methods for the prevention, treatment, or amelioration of cancer.